louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02154503: Evaluating the Efficacy of Microneedling in the Treatment of Androgenetic Alopecia
Official title: Evaluating the Efficacy of Microneedling in the Treatment of Androgenetic Alopecia- Pilot Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Androgenetic Alopecia
Lead sponsor: Vancouver General Hospital
Sponsor class: OTHER
First posted: 2014-06-03
Enrollment: 20
Sex: MALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Androgenetic Alopecia is the most common non scarring alopecia worldwide. Treatment of which has been limited with few options for medical and surgical treatment, the cost of the latter being prohibitive for many. Recently there have been several new modalities proposed as treatment, namely Microneedling and Platelet Rich Plasma.

Microneedling has been shown to overexpress hair growth factors which may enhance or stimulate miniaturized hairs to grow. It has also been shown to increase the absorption of topical products significantly. The exact mechanism of action of Microneedling is still being delineated.

In this study, we aim to do a half lesional study with global photographs and hair counts done at the start of , week four and week twelve. Patients would be needled once weekly after application of topical anaesthetic (5% EMLA). If by week six there is significant regrowth (\>30%), then total lesional needling will be done. Patients will only be using topical 5% Minoxidil throughout the study as this will prolong the effects of the regrowth.


Eligibility criteria: Inclusion Criteria:

1. Men between the ages 18-65.
2. Disease Stage: Norwood Hamilton IIIa-IV.
3. Length of time with disease \< 10 years.

Exclusion Criteria:

1. Must not have other concurrent hair disease.
2. Have not used any oral anti androgen (Finasteride or Dutasteride) in the past six months. If so, a washout period is needed. One month for Finasteride and three months for Dutasteride.
3. Patients under the age of 18.
4. Patients who are unable to offer consent.

Primary outcomes:
measure: Hair caliber diameter and hair counts will be measured on both the treated and untreated sides.
timeFrame: three months
Secondary outcomes:
measure: Adverse effects of the procedure will be recorded.
timeFrame: three months
Other outcomes:
Locations:
city: Vancouver
country: Canada
facility: The Skin Care Centre
state: British Columbia
Study officials:
affiliation: University of British Columbia
name: Jerry Shapiro, MBBS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04859803: Rhomboid Intercostal and Sub-serratus Block
Official title: Efficacy of Rhomboid Intercostal Block With Sub-serratus Block on Perioperative Analgesia in Patients Undergoing Gynecomastia Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Rhomboid Intercostal Block
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2021-04-26
Enrollment: 60
Sex: MALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The rhomboid intercostal block (RIB) can provide good analgesia effects after thoracic surgery . The ultrasound-guided RIB is novel analgesic techniques recently described by Elsharkawy et al. . Additionally, the RISS block anesthetizes the lateral cutaneous branches of the thoracic intercostal nerves and can be used in multiple clinical settings for chest wall and upper abdominal analgesia. However, the analgesic effects of the RISS block after breast surgery have not been analyzed through a randomized-controlled trial.


Eligibility criteria: Inclusion criteria Adult patients between 18-50 years. ASA physical status I and II Male gender

Exclusion criteria Patient refusal Contraindications to regional anesthesia Known allergy to local anesthetics Bleeding disorders Use of any anti-coagulants Inability to provide informed consent ASA III-IV

-

Primary outcomes:
measure: morphine consumption
timeFrame: 24 hours
Secondary outcomes:
measure: recovery time
timeFrame: 1 hour
measure: Pain evaluation
timeFrame: 24 hous
measure: time to first analgesia
timeFrame: 24 hous
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of Medicine, Cairo University.
Study officials:
References:
Clinical trial NCT05725603: Clinical and Anatomical Evaluation of Healing of Lesions of the Subscapular Tendon
Official title: Clinical and Anatomical Evaluation of Healing of Lesions of the Subscapular Tendon
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Shoulder Injuries
Lead sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche
Sponsor class: OTHER
First posted: 2023-02-13
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: This study is based on the hypothesis that fatty infiltration postoperative is not or only slightly modified after an atomic repair of lesions of the subscapularis tendon according to a new arthroscopic classification.

Detailed description: After repair of isolated lesions of the subscapularis, it is observed, in nearly half of the cases, a increased fatty infiltration of the subscapularis muscle indicating a probable persistence of the tendon rupture while the Healing failure rate is recognized as moderate (about 15%).

This study is based on the hypothesis that fatty infiltration postoperative is not or only slightly modified after an atomic repair of lesions of the subscapularis tendon according to a new arthroscopic classification.

Eligibility criteria: Inclusion Criteria:

* Patient, male or female, aged ≥ 18 years
* Patient who has undergone surgical repair for a rupture or rotator cuff injury involving the subscapularis tendon between April and September 2016 and between May 2018 and January 2019
* Patient with a lesion of the subscapularis tendon characterized with arthroscopic classification
* Patient who has previously participated in the classification study of subscapularis tendon injuries based on findings arthroscopy conducted only at the Jean Mermoz Hospital

Exclusion Criteria:

* Patient with a contraindication to MRI

Primary outcomes:
measure: Tendon scarring
timeFrame: 1 day
Secondary outcomes:
measure: Fatty infiltration
timeFrame: 1 day
Other outcomes:
Locations:
city: Lyon
country: France
facility: Hôpital Privé Jean Mermoz
Study officials:
References:
Clinical trial NCT01243203: Smoking Cessation Program in the Preadmission Clinic: The Use of a Teachable Moment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Smoking
Keywords: Smoking, surgery, Anesthesia, quit
Lead sponsor: University Health Network, Toronto
Sponsor class: OTHER
Collaborators: name: Pfizer
First posted: 2010-11-18
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: The Objective of this study is to introduce a practically feasible multifaceted intervention in the preadmission clinic to help reduce smoking in preoperative surgical patients. The investigators aim to study the effectiveness of such a program in promoting positive change in smoking behavior among patients before surgery. The forced abstinence enforced on patients during hospital stay for their surgery can also be used to help smokers remain tobacco free long term. A significant percentage of surgical patients will be receptive to smoking cessation interventions in the preadmission clinic and will refrain from smoking at 24 and 52 weeks after starting the treatment.


Eligibility criteria: Inclusion Criteria:

* The investigators will recruit patients who are assessed in preadmission clinic and scheduled for elective surgical procedures within the next 8 to 30 days.
* Patients should be 18 yrs of age, have smoked an average 10 cigarettes/day or more during the previous year and had no period of smoking abstinence longer than 3 months in the past year.

Exclusion Criteria:

* current pregnancy, breastfeeding;
* major depression, panic disorder, psychosis, or bipolar disorder within the prior year;
* use of nicotine replacement or bupropion within the previous 3 months;
* cardiovascular disease within the past 6 months;
* a serious or unstable disease within the past 6 months;
* drug or alcohol abuse or dependence within the past year;
* and use of tobacco products other than cigarettes or marijuana use within the previous month;
* participating in any other studies
* Patients who cannot understand English or have any form of cognitive impairment will be excluded.

Primary outcomes:
measure: A significant percentage of surgical patients will be receptive to smoking cessation interventions in the preadmission clinic and will refrain from smoking at 24 and 52 weeks after starting the treatment.
timeFrame: 2 years
Secondary outcomes:
measure: Patients who receive interventions but do not quit smoking will have reduced number of cigarettes consumed /day or improved "stage of change" (determined by Prochaska and DiClemente's Model) at 24 and 52 weeks after starting the treatment.
timeFrame: 2 years
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: University Health Network, Department of Anesthesai
state: Ontario
Study officials:
References:
Clinical trial NCT02942303: The Impact of Botulinum Toxin on Brow Height and Morphology: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Brow Lifting
Keywords: Botulinum Toxin, Rejuvenation, Brow lift, Eyebrow.
Lead sponsor: St Joseph University, Beirut, Lebanon
Sponsor class: OTHER
First posted: 2016-10-24
Enrollment: 30
Sex: FEMALE
Minimum age (years): 28
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to describe three safe and reproducible techniques for brow lifting using botulinum toxin. It will also describe the effect of 2 techniques on the eyebrow shape using quantitative, objective measurements and satisfaction scales.


Eligibility criteria: Inclusion Criteria:

* Consecutive 30 female patients presenting to our clinic for brow lifting with botulinum toxin will be randomized to receive one of the two injection techniques

Exclusion Criteria:

* Patients with previous periorbital/forehead surgery
* Patients who plucked the upper eyebrow margin
* Patients with eyebrow tatoos
* Patients with upper face botulinum toxin injection in the past 12 months
* Patients with resorbable upper face fillers injection in the past 12 months
* Patients with previous permanent upper face fillers injection
* Pregnant patients
* Lactating patients
* Patients with preexisting neuromuscular conditions (myasthenia gravis, Eaton Lambert syndrome)
* Patients using medication that could potentiate the effect of botulinum (ex: aminoglycoside antibiotics)
* Patients with sensitivity to botulinum toxin or human albumin

Primary outcomes:
measure: Objective assessment
timeFrame: 15 days post treatment
Secondary outcomes:
measure: Patient satisfaction
timeFrame: 15 days post treatment
Other outcomes:
Locations:
city: Beirut
country: Lebanon
facility: Hotel Dieu De France
state: Aschrafieh
Study officials:
References:
citation: El-Khoury JS, Jabbour SF, Awaida CJ, Rayess YA, Kechichian EG, Nasr MW. The Impact of Botulinum Toxin on Brow Height and Morphology: A Randomized Controlled Trial. Plast Reconstr Surg. 2018 Jan;141(1):75-78. doi: 10.1097/PRS.0000000000003919.
Clinical trial NCT02670603: A Trial of Evonail® Solution for Prevention or Treatment of Onycholysis
Official title: A Prospective Randomized Controlled Trial of Evonail® Solution for Prevention or Treatment of Onycholysis in Breast Cancer Patients Who Received Neoadjuvant/Adjuvant Docetaxel Chemotherapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Breast Cancer
Docetaxel Chemotherapy
Lead sponsor: Samsung Medical Center
Sponsor class: OTHER
First posted: 2016-02-02
Enrollment: 100
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study is a prospective randomized controlled study of EVONAIL® solution for prevention or treatment of onycholysis in patients with breast cancer receiving docetaxel chemotherapy.


Eligibility criteria: Inclusion Criteria:

* Patients with breast cancer receiving adjuvant/neoadjuvant docetaxel chemotherapy

Exclusion Criteria:

* Patients with breast cancer receiving palliative docetaxel chemotherapy
* Patients having onycholysis before docetaxel treatment

Primary outcomes:
measure: The incidence of onycholysis Gr 2 or more
timeFrame: 12weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
Study officials:
References:
citation: Kim JY, Ok ON, Seo JJ, Lee SH, Ahn JS, Im YH, Park YH. A prospective randomized controlled trial of hydrating nail solution for prevention or treatment of onycholysis in breast cancer patients who received neoadjuvant/adjuvant docetaxel chemotherapy. Breast Cancer Res Treat. 2017 Aug;164(3):617-625. doi: 10.1007/s10549-017-4268-7. Epub 2017 May 9.
Clinical trial NCT01672203: Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Incidence in Patients With Central Versus Peripheral Embolism
Official title: Incidence of CTEPH in Dependence of Thrombus Location in Patients With Acute Pulmonary Embolism and Index Fibrinolysis
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: CTEPH
Lead sponsor: University of Cologne
Sponsor class: OTHER
First posted: 2012-08-24
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients who were hospitalized for acute pulmonary embolism at the University Hospital of Cologne.

Brief summary: Chronic thromboembolic pulmonary hypertension (CTEPH) has been associated with increased morbidity and mortality. Patients with pulmonary embolism (PE) have elevated risk for development of CTEPH. It is not known, whether the location of pulmonary embolism (central vs. peripheral) nor fibrinolysis have an impact of CTEPH incidence. This study has been performed to assess the CTEPH incidence in different populations: in patients with central vs. peripheral PE and in patients with or without fibrinolysis therapy for PE.

Detailed description: The embolus localization during index pulmonary embolism might be of potential relevance for CTEPH development.

In the present study patients with confirmed pulmonary embolism for at least 12 months will be screened for CTEPH. The incidence of CTEPH will be correlated to thrombus location (central vs. peripheral) and the index use of fibrinolysis.

Eligibility criteria: Inclusion Criteria:

* acute pulmonary embolism for at least 12 months

Exclusion Criteria:

* known pulmonary hypertension other than CTEPH

Primary outcomes:
measure: CTEPH
timeFrame: participants will be followed at least one year after acute pulmonary embolism, an expected average of 5 years follow-up is estimated
Secondary outcomes:
Other outcomes:
Locations:
city: Cologne
country: Germany
facility: Heart Center of the University Hospital of Cologne
state: NRW
Study officials:
affiliation: University of Cologne
name: Fikret Er, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00959803: Study Of Single Ascending And Multiple Doses Of PF-04447943 In Japanese Subjects.
Official title: An Investigator- And Subject-Blind Phase 1 Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04447943 After Administration Of Single Oral Doses To Healthy Young Adult Japanese Subjects And Multiple Oral Doses To Healthy Elderly Japanese Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: Phase 1
Pharmacokinetics
Healthy Young Adult
Japanese
Healthy Elderly
Alzheimer disease
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2009-08-17
Enrollment: 17
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This study is designed to investigate the safety, tolerability, and pharmacokinetics of PF-04447943 after single and multiple-dose administration to healthy young adult and elderly Japanese subjects, respectively.


Eligibility criteria: Inclusion Criteria:

* For young cohort, healthy male and/or female Japanese of non-child bearing potential between the age of 18 and 55 years, inclusive.
* For elderly cohort, healthy male and/or female Japanese of non-child bearing potential between the age of 65 and 85 years, inclusive.
* Body Mass Index (BMI) between 17.5 to 30.5 kg/m2, and a total body weight \>50 kg (110 lbs).

Exclusion Criteria:

* Pregnant or nursing women; women of childbearing potential.
* Males who are unwilling to abstain from sexual intercourse or use a condom with all child-bearing potential women for the duration of the study.

Primary outcomes:
measure: AEs (spontaneous and solicited). Change from baseline in vital signs.
timeFrame: Day 0 to follow up visit after Study Day 5(single dose arm) and Day 11(multiple dose arm)
measure: ECG and clinical safety laboratory endpoints, including a complete blood count, a full chemistry panel (including electrolytes and hepatic transaminases) and urinalysis.
timeFrame: Screening visit to follow up visit after Study Day 5(single dose arm) and Day 11(multiple dose arm)
measure: Pharmacokinetic (single): AUClast, Cmax, Tmax
timeFrame: Day 1 to day 5
measure: Pharmacokinetic(multiple): AUCt, Cmax and Tmax on Days 1 and 7, and Ctrough on Days 2, 3, 4 and 7.
timeFrame: Day 1 to day 11
Secondary outcomes:
Other outcomes:
Locations:
city: Glendale
country: United States
facility: Pfizer Investigational Site
state: California
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT06721403: Psychatric Effect of Ectopic Pregnancy
Official title: Assessment of Anxiety,Depressive Symptoms &PTSD in Cases of Post Ectopic Pregnancy
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Ectopic Pregnancy
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2024-12-06
Enrollment: 85
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All pregnant women 18:45 years old presented with ectopic pregnancy

Brief summary: Assessment of anxiety,depressive symptoms and post traumatic stress after ectopic pregnancy Determine factors associated with development of anxiety,depressive symptoms and post-traumatic stress after ectopic pregnancy

Detailed description: Ectopic pregnancy is any pregnancy in which the fertilized ovum implants outside the intrauterine cavity. More than 95 percent of ectopic pregnancies occur in the fallopian tubes.

Another 2.5 percent occur in the cornua of the uterus, and the remainder are found in the ovary, cervix or abdominal cavity.

Ectopic pregnancy causes major maternal morbidity and mortality, with pregnancy loss, and its incidence is increasing worldwide.

Previous ectopic pregnancy becomes a more significant risk factor with each successive occurrence. With one previous ectopic pregnancy treated by linear salpingostomy, the recurrence rate ranges from 15 to 20 percent, depending on the integrity of the contralateral tube.

The unanticipated and sudden loss of a pregnancy can be a devastating and traumatic experience resulting in high levels of psychological morbidity for some women.

EPLs can significantly contribute to the overall burden of psychopathology within a population. Recognition of this impact is important, so that severely affected individuals may be screened and treated appropriately. Further research to establish risk factors to promptly identify and treat these patients, and to optimize their management, is crucial"

Eligibility criteria: Inclusion Criteria:

* All pregnant woman 18:45 years old presented with ectopic pregnancy.

Exclusion Criteria:

* intrauterine pregnancy
* previous diagnosis of psychiatric disorders
* Unwell to give consent

Primary outcomes:
measure: Effect of ectopic pregnancy
timeFrame: Within one week
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Assiut University
name: Ahmed Abbas, Prof
role: STUDY_DIRECTOR
References:
citation: Farren J, Jalmbrant M, Ameye L, Joash K, Mitchell-Jones N, Tapp S, Timmerman D, Bourne T. Post-traumatic stress, anxiety and depression following miscarriage or ectopic pregnancy: a prospective cohort study. BMJ Open. 2016 Nov 2;6(11):e011864. doi: 10.1136/bmjopen-2016-011864.
Clinical trial NCT01680302: Effect of 3 Years of Exercise on Development of Atrial Fibrillation
Official title: Effect of 3 Years of Exercise on Development of Atrial Fibrillation - A "Generation 100" Substudy
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Atrial Fibrillation
Keywords: Atrial fibrillation
Prevention
Exercise
Lead sponsor: Norwegian University of Science and Technology
Sponsor class: OTHER
Collaborators: name: St. Olavs Hospital
First posted: 2012-09-07
Enrollment: 1567
Sex: ALL
Minimum age (years): 70
Maximum age (years): 75
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This is a substudy of "Generation 100". In that study, 4000 healthy persons between 70 and 75 will be randomised to a moderate intensity training group, a high intensity training group or control group, with 3 years of exercise. The investigators will follow these persons and register all who develop atrial fibrillation during these 3 years, and at follow-up after ended intervention to see if there is differences in the number of persons who develop atrial fibrillation in the 3 groups.


Eligibility criteria: Inclusion Criteria:

* Participating in the "Generation 100" study

Exclusion Criteria:

-

Primary outcomes:
measure: Number of persons who develop atrial fibrillation during the 3 year intervention period
timeFrame: 3 years
Secondary outcomes:
measure: Number of persons who develop atrial fibrillation during the 6 years after randomisation
timeFrame: 6 years
Other outcomes:
Locations:
city: Trondheim
country: Norway
facility: Norwegian University of Science and Technology
Study officials:
affiliation: St. Olavs Hospital
name: Jan Paal Loennechen, PhD
role: STUDY_CHAIR
References: